Results from a study investigating the epidemiology and treatment of Atopic Dermatitis in the United Kingdom were posted on ClinicalTrials.gov on 2025-06-06. The study enrolled a substantial cohort of 148,166 participants.
Background
Atopic dermatitis (AD), commonly known as eczema, is one of the most prevalent skin conditions globally, affecting a significant proportion of children in developed countries and increasingly in less developed regions. Despite its widespread occurrence, precise estimates of its prevalence and the specific demographic groups most affected in the UK have been unclear. Furthermore, there has been a lack of in-depth analysis regarding the treatment options utilized for AD within the UK healthcare system. Most individuals with eczema are managed by their general practitioner (GP), with only a smaller subset requiring specialist care. Understanding these trends is crucial for optimizing patient management and resource allocation.
Trial design
This completed observational study, which did not have a designated phase, enrolled 148,166 participants. The study focused on conditions including Atopic Dermatitis Eczema, Atopic Dermatitis, and Eczema. As an epidemiological study, it did not involve specific interventions or primary endpoints in the traditional sense of an interventional trial, but rather aimed to characterize treatment patterns and healthcare utilization.
Key results
The study detailed prescription rates for various Atopic Dermatitis-related treatments and referral patterns for participants with active Atopic Dermatitis:
- For Emollients and Soap Substitutes, 76095 Participants received prescriptions.
- For Mild Topical Corticosteroids (TCS), 40478 Participants received prescriptions.
- For Moderate Topical Corticosteroids (TCS), 19575 Participants received prescriptions.
- For Potent Topical Corticosteroids (TCS), 34997 Participants received prescriptions.
- For Very Potent Topical Corticosteroids (TCS), 6478 Participants received prescriptions.
- For Topical Calcineurin Inhibitors (TCI), 2683 Participants received prescriptions.
- For Topical Antimicrobials, 19378 Participants received prescriptions.
- For Antihistamin, 29041 Participants received prescriptions.
- For Systemic Immuno-modulatory Therapy, 2785 Participants received prescriptions.
- For Oral Corticosteroids, 12087 Participants received prescriptions.
- Specialist Referrals were observed at a rate of 5.0 Referrals per 100 person-years.
- Primary Care Referrals were observed at a rate of 112.0 Consultations per 100 person-years.
What this means
These results provide a comprehensive overview of real-world treatment practices and healthcare engagement for Atopic Dermatitis in the UK. The high number of participants receiving emollients and various strengths of topical corticosteroids underscores their foundational role in AD management. The data also highlights the significant volume of primary care consultations compared to specialist referrals, reinforcing the role of general practitioners in managing the majority of AD cases. This epidemiological insight can inform public health strategies, clinical guidelines, and resource allocation to better support individuals living with Atopic Dermatitis.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT03823794, titled "Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)", were posted on 2025-06-06 on clinicaltrials.gov.